<div id="readability-page-1"><p>Gabelli Funds LLC lowered its position in shares of  Labcorp Holdings Inc. (NYSE:LH - Free Report) by 19.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,261 shares of the medical research company's stock after selling 8,000 shares during the period. Gabelli Funds LLC's holdings in Labcorp were worth $8,345,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>After 15% L3Harris Price Drop, Is It Time to Buy or Time to Fly?</li></ul><p>A number of other hedge funds and other institutional investors have also made changes to their positions in LH. Thurston Springer Miller Herd &amp; Titak Inc. acquired a new stake in shares of  Labcorp during the 4th quarter worth approximately $26,000.  JPL Wealth Management LLC acquired a new stake in shares of  Labcorp during the 3rd quarter worth approximately $28,000.  Eagle Bay Advisors LLC acquired a new stake in shares of  Labcorp during the 4th quarter worth approximately $29,000.  Beacon Financial Strategies CORP acquired a new stake in shares of  Labcorp during the 4th quarter worth approximately $33,000.  Finally, Headlands Technologies LLC increased its holdings in shares of  Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company's stock worth $34,000 after buying an additional 96 shares during the last quarter. Institutional investors and hedge funds own  95.94% of the company's stock. </p><h2>Insider Activity</h2><p>In other news, EVP Brian J. Caveney sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total value of $429,465.00. Following the completion of the transaction, the executive vice president owned 30,107 shares of the company's stock, valued at approximately $8,619,935.17. This trade represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the firm's stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the transaction, the executive vice president directly owned 2,579 shares of the company's stock, valued at approximately $734,782.89. The trade was a 17.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 16,656 shares of company stock valued at $4,524,961. 0.84% of the stock is currently owned by company insiders. </p><h2>Labcorp Trading Down 1.0%</h2><ul><li>Why This Defense ETF Could Keep Rallying as the Iran Conflict Escalates</li></ul><p>NYSE LH opened at $252.96 on Wednesday. The firm has a 50 day simple moving average of $264.58 and a 200-day simple moving average of $265.55. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. Labcorp Holdings Inc. has a one year low of $239.75 and a one year high of $293.72. The firm has a market cap of $20.74 billion, a price-to-earnings ratio of 22.41, a PEG ratio of 1.79 and a beta of 0.91. </p><p>Labcorp (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. During the same quarter last year, the firm posted $3.84 earnings per share. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS.  Equities research analysts anticipate that  Labcorp Holdings Inc. will post 17.99 EPS for the current fiscal year. </p><h2>Labcorp Dividend Announcement</h2><ul><li>Gold, Copper, and Missiles: 3 Big Dividend Raises After a Breakout Year</li></ul><p>The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp's dividend payout ratio (DPR) is presently 25.51%. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several brokerages have weighed in on LH. Robert W. Baird  set a $334.00 target price on shares of Labcorp in a research note on Friday, May 1st. Evercore  reaffirmed an &#34;outperform&#34; rating and set a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Weiss Ratings  reaffirmed a &#34;buy (b-)&#34; rating on shares of Labcorp in a research note on Friday, May 8th. JPMorgan Chase &amp; Co. increased their target price on shares of Labcorp from $319.00 to $330.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, February 18th. Finally, Piper Sandler increased their target price on shares of Labcorp from $270.00 to $300.00 and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, February 24th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $308.00.</p><p><b>Get Our Latest Research Report on LH</b></p><h2>About Labcorp</h2> (Free Report)<p>Laboratory Corporation of America Holdings, commonly known as Labcorp <span>NYSE: LH<span></span></span>, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.  </p><p>Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.</p><h2>See Also</h2><ul><li>Five stocks we like better than Labcorp</li><li>HIVE Weaponizes Power for an AI Pivot</li><li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li><li>Brady Corp Wires Up a Massive AI-Powered Breakout</li><li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxI"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Labcorp Right Now?</h2><p>Before you consider Labcorp, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.</p><p>While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Gabelli Funds LLC reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 19.4% in Q4, now holding 33,261 shares valued at $8.34 million. Other institutional investors also adjusted their positions. Insider sales included EVP Brian J. Caveney selling 1,500 shares and EVP Der Vaart Sandra D. Van selling 548 shares. Labcorp's stock opened at $252.96, with a market cap of $20.74 billion and a recent quarterly EPS of $4.25, exceeding estimates.</p>

Labcorp Holdings Inc. $LH Shares Sold by Gabelli Funds LLC